Rheumatology

Individuals with rheumatoid arthritis receiving the oral Janus kinase inhibitor upadacitinib have higher rates of herpes zoster than those being treated with methotrexate alone or in combination with adalimumab, research shows.

A population-based cohort study using the 2017 EULAR/American College of Rheumatology criteria for dermatomyositis has identified a higher incidence, prevalence, and associated mortality rate than previously reported.

Individuals with rheumatoid arthritis have a significantly higher risk for serious infections while receiving TNF inhibitor therapy than those with psoriatic arthritis, Norwegian researchers report.

Click through to read more about this announcement

TNF inhibitor monotherapy is associated with a lower risk for COVID-19-related hospitalization or death than other common immunomodulatory treatments given to people with immune-mediated inflammatory diseases, research suggests.

More information about this decision here

Approximately half of patients with rheumatoid arthritis in sustained remission could feasibly taper or stop DMARD treatment for at least 12 months without experiencing relapse, results of the phase 3 RETRO study indicate.

Premenopausal women with rheumatoid arthritis are twice as likely as their healthy counterparts to have subclinical diastolic dysfunction, Korean study findings indicate.

Click through for further details on this announcement

A systematic review and network meta-analysis has compared different drug treatments for pain relief in people with knee or hip osteoarthritis, finding that certain NSAIDs may have the greatest benefit, while opioids are associated with increased risk for harm.

The majority of patients with rheumatoid arthritis or psoriatic arthritis on Janus kinase inhibitor therapy produce an antibody response to vaccines against SARS-CoV-2, researchers report.

EULAR has updated its points to consider on the use of immunomodulatory therapies for the treatment of COVID-19 in light of the most recent evidence.

Findings from the phase 2 NOBILITY trial suggest that the addition of the type II anti-CD20 antibody obinutuzumab to standard therapy may improve renal outcomes for patients with proliferative lupus nephritis.

Almost two-thirds of patients with rheumatoid arthritis say that they have not discussed treatment goals with their healthcare provider, yet those who have such discussions report greater improvements in disease activity, US study data show.

The majority of people with systemic lupus erythematosus who respond to mRNA COVID-19 vaccines also generate an antibody response against emerging SARS-CoV-2 variants, albeit with reduced neutralizing activity against variants bearing the E484K mutation, researchers report.

Systemic lupus erythematosus is significantly associated with impaired survival among older women with early breast cancer, research findings show.

Levels of the adipocytokines adiponectin, leptin, and fibroblast growth factor-21 are significantly associated with both low lean mass and excess adiposity in people with rheumatoid arthritis, US study findings indicate.

Discontinuing denosumab after 1 year of treatment quickly leads to reversal of its inhibitory effect on bone turnover markers and improvements in bone mineral density among people using glucocorticoids for rheumatoid arthritis, research shows.

People with psoriatic arthritis prioritize oral administration, avoiding severe complications, and maintaining the ability to attend work and resume normal activities over clinical measures of efficacy when it comes to medication preferences, research suggests.

Treatment with secukinumab improves outcomes for people with nonradiographic axial spondyloarthritis across different subgroups, but those with objective signs of inflammation may experience the greatest benefits, suggests a post-hoc analysis of the PREVENT trial.